SEC Form 4 · accession 0001578563-18-000005
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon Pedder
Director
Period of report
Apr 6, 2018
Accepted (ET)
Apr 10, 2018 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.14 | Apr 6, 2018 | A | 16,714 | A | — | Apr 6, 2028 | Common Stock | 16,714 | 16,714 | D |
Explanation of responses
- F1The grant shall vest one-third on each of the first, second and third anniversaries of the date of grant, provided Dr. Pedder is then a director of the Company.